# A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

> **NCT03368664** · PHASE3 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 16 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Alemtuzumab GZ402673
- **DRUG:** Glatiramer acetate
- **DRUG:** Beta-Interferon
- **DRUG:** Methylprednisolone
- **DRUG:** Ranitidine
- **DRUG:** Ceterizine
- **DRUG:** Dexchlorpheniramine
- **DRUG:** Paracetamol
- **DRUG:** Acyclovir
- **DRUG:** Prednisolone
- **DRUG:** Diphenydramine
- **DRUG:** Other H1 antagonist
- **DRUG:** Other H1 antagonist

## Key facts

- **NCT ID:** NCT03368664
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-24
- **Primary completion:** 2021-05-04
- **Final completion:** 2025-09-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Enrolment formally closed earlier than planned due to recruitment challenges.
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03368664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03368664, "A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03368664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*